Get all your news in one place.
100's of premium titles.
One app.
Start reading
MarketBeat
MarketBeat
Business
Jeffrey Neal Johnson

Merck Writes a $9.2 Billion Check for a Flu Drug That Could Change Everything

In one of the most decisive strategic moves in the biotech sector this year, pharmaceutical titan Merck & Co. (NYSE: MRK) has committed a formidable $9.2 billion in cash to acquire Cidara Therapeutics (NASDAQ: CDTX).

The announcement immediately sent Cidara’s stock price rocketing over 100%, a clear victory for its investors. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.